Hydrolyzed Collagen Supplement Firm Agrees To Order Barring Claims To Grow Bone, Cartilage

Claims of bone and cartilage growth, along with relief of joint pain, shot down by FTC. But company says claims “are adequately substantiated by existing studies and scientific literature.”

• Source: Shutterstock

The Federal Trade Commission settles a complaint against ZyCal Bioceuticals Healthcare Company Inc. about claims that its Ostinol hydrolyzed collagen dietary supplements grow bone and cartilage to relieve joint pain.

More from Legal

EU Probiotics Deadlock: Ombudsman Finds ‘No Maladministration’ By The Commission

 
• By 

In response to an IPA Europe complaint, European Ombudsman Emily O’Reilly finds that the Commission’s interpretation of EU food legislation in relation to probiotics is “reasonable and in line with the main goal of this legislation, which is to ensure a high level of consumer protection.”

Uncertainty Abounds With SEC Climate Reporting Rule Tied Up In Courts

 
• By 

Despite questions surrounding the SEC rule, including disputes being litigated in the US Eighth Circuit, companies must prepare to meet the new climate disclosure requirements in addition to related mandates in California and abroad. Experts emphasize opportunities beyond compliance.

Dietary Supplements Category Ranks Second For Food Fraud In EU

 
• By 

Report from European Commission's Alert and Cooperation Network finds EU consumers are being deceived by companies marketing supplements making unauthorized health claims and containing unapproved ingredients. 

Deference No More: More Challenges Against US FDA After Supreme Court Tosses Chevron Doctrine?

 
• By 

The Supreme Court’s 6-3 ruling is expected to have a minimal impact on drug approvals and other scientific determinations, but matters steeped in the interpretation of regulation and statute, such as marketing exclusivity, could face a heightened risk of challenge, legal experts say.

More from Policy & Regulation